Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.75 |
| ▸ | TYK2 | P29597 | 16/20 | 0.54 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947332 | 1.00 | JAK2 (0.75) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL24776106 | 0.91 | JAK2 (0.70) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL29947288 | 0.91 | JAK2 (0.70) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL24776107 | 0.89 | JAK2 (0.74) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL29947165 | 0.89 | JAK2 (0.74) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL31280374 | 0.86 | JAK2 (0.56) | JAK2TYK2JAK1 | |
| SCHEMBL22647319 | 0.85 | JAK2 (1.00) | JAK2TYK2JAK1 | |
| SCHEMBL24782683 | 0.85 | JAK2 (0.70) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL26629677 | 0.85 | JAK2 (0.79) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL31280055 | 0.85 | JAK2 (0.56) | JAK2TYK2JAK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337648-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | claimed |
| US-20240124421-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-04-18 | — | — | US | disclosed |
| EP-4337648-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | JAK2 2/4885TYK2 1/4885JAK1 4/4885 |
| US-20240124421-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | JAK2 2/4885TYK2 1/4885JAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.